Skip to main content

RA Capital Management — Portfolio, Page 16

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$49.1B
Total invested
$128.6M
Avg. check
20
Industries
Biotechnology 17Health Care 14Therapeutics 10Medical 8Pharmaceutical 7Life Science 5+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 361384 of 453
Day One Biopharmaceuticals
July 2024

Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.

Biopharma · South San Francisco$175.0M Post Ipo Equity
Magenta Medical
July 2024

Magenta Medical is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.

Health Care · Kadima$105.0M Series Unknown
LENZ Therapeutics
July 2024

LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.

Health Care · Del Mar$30.0M Post Ipo Equity
AM Batteries
July 2024

AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.

Electronics · Chelmsford$2.2M Grant
Frontier Medicines
June 2024

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Biopharma · San Francisco$20.0M Series C
Bright Peak Therapeutics
June 2024

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

Biotechnology · Allschwil$90.0M Series C
Ajax Therapeutics
May 2024

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Biotechnology · Cambridge$95.0M Series C
Bluejay Therapeutics
May 2024

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Biotechnology · San Mateo$182.0M Series C
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
SeLux Diagnostics
April 2024

SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.

Biotechnology · Charlestown$48.0M Series D
CervoMed
March 2024

CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.

Health Care · Boston$149.4M Post Ipo Debt
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post Ipo Equity
Capstan Therapeutics
March 2024

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

Biotechnology · San Diego$175.0M Series B
Napigen
March 2024

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.

Agriculture · WilmingtonGrant
MMI
February 2024

MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.

Health Care · Pisa$110.0M Series C
ProfoundBio
February 2024

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Biotechnology · Seattle$112.0M Series B
Tyra Biosciences
February 2024

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$200.0M Post Ipo Equity
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post Ipo Equity
Verve Therapeutics
November 2023

Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.

Biotechnology · Boston$143.8M Post Ipo Equity
Forward Therapeutics
October 2023

Forward Therapeutics is a biopharma comapny targeting treatment of chronic inflammatory disorders.

Health Care · Palm Beach Gardens$50.0M Series A
Rampart Bioscience
October 2023

Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.

Biopharma · La Jolla$85.0M Series A
Aiolos Bio
October 2023

Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.

Biopharma · San Francisco$245.0M Series A
Harpoon Therapeutics
October 2023

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.

Biotechnology · South San Francisco$100.0M Post Ipo Equity
Ventricle Health
October 2023

Ventricle Health offers evidence-based therapy, remote patient monitoring, patient education, and advocacy services for cardiac care.

Health Care · Greensboro$8.0M Seed

Where RA Capital Management invests

Biotechnology17
Health Care14
Therapeutics10
Medical8
Pharmaceutical7
Life Science5

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 20 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Aiolos Bio received $245.0M in a Series A round. RA Capital Management's total known invested capital is $49.1B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $128.6M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Day One Biopharmaceuticals, Magenta Medical, LENZ Therapeutics, AM Batteries, Frontier Medicines. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →